Cargando…

Tamoxifen Modulates the Immune Landscape of the Tumour Microenvironment: The Paired Siglec-5/14 Checkpoint in Anti-Tumour Immunity in an In Vitro Model of Breast Cancer

Since the role of sialome–Siglec axis has been described as a regulatory checkpoint of immune homeostasis, the promotion of stimulatory or inhibitory Siglec-related mechanisms is crucial in cancer progression and therapy. Here, we investigated the effect of tamoxifen on the sialic acid–Siglec interp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wielgat, Przemyslaw, Rogowski, Karol, Czarnomysy, Robert, Wawrusiewicz-Kurylonek, Natalia, Narejko, Karolina, Bielawski, Krzysztof, Car, Halina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10057974/ https://www.ncbi.nlm.nih.gov/pubmed/36982588 http://dx.doi.org/10.3390/ijms24065512

Ejemplares similares

The Paired Siglecs in Brain Tumours Therapy: The Immunomodulatory Effect of Dexamethasone and Temozolomide in Human Glioma In Vitro Model
por: Wielgat, Przemyslaw, et al.
Publicado: (2021)

Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy
por: Wielgat, Przemyslaw, et al.
Publicado: (2020)

SARS-CoV-2 Attacks in the Brain: Focus on the Sialome
por: Wielgat, Przemyslaw, et al.
Publicado: (2022)

Cell Membrane Sialome: Sialic Acids as Therapeutic Targets and Regulators of Drug Resistance in Human Cancer Management
por: Jastrząb, Patrycja, et al.
Publicado: (2023)

Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects
por: Wielgat, Przemyslaw, et al.
Publicado: (2020)

Sialic acids as cellular markers of immunomodulatory action of dexamethasone on glioma cells of different immunogenicity
por: Wielgat, Przemyslaw, et al.
Publicado: (2018)

Selective H3 Antagonist (ABT-239) Differentially Modifies Cognitive Function Under the Impact of Restraint Stress
por: Trofimiuk, Emil, et al.
Publicado: (2021)

Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade
por: Appleton, Elizabeth, et al.
Publicado: (2021)

The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression
por: Zheng, Yayun, et al.
Publicado: (2020)

Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9
por: Rodriguez, Ernesto, et al.
Publicado: (2021)

Analysis of a novel immune checkpoint, Siglec‐15, in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

Culprits of PDAC resistance to gemcitabine and immune checkpoint inhibitor: Tumour microenvironment components
por: Hsu, Sheng-Kai, et al.
Publicado: (2022)

Sialic Acid—Modified Nanoparticles—New Approaches in the Glioma Management—Perspective Review
por: Wielgat, Przemyslaw, et al.
Publicado: (2021)

Obstacles for T-lymphocytes in the tumour microenvironment: Therapeutic challenges, advances and opportunities beyond immune checkpoint
por: Verma, Navin Kumar, et al.
Publicado: (2022)

Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
por: Yang, Xiuxiu, et al.
Publicado: (2021)

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2017)

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
por: Sundar, Raghav, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review
por: Petrelli, Fausto, et al.
Publicado: (2021)

Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
por: Sun, Qian, et al.
Publicado: (2023)

Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy
por: Tilsed, Caitlin M., et al.
Publicado: (2022)

Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
por: Zhong, Fengyun, et al.
Publicado: (2023)

Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy
por: Li, Guan-Zhang, et al.
Publicado: (2019)

Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types
por: Wu, Yuliang, et al.
Publicado: (2022)

Correction to: Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics
por: Zhong, Fengyun, et al.
Publicado: (2023)

The Role of Siglec-G on Immune Cells in Sepsis
por: Royster, William, et al.
Publicado: (2021)

Relationship between immune checkpoint proteins, tumour microenvironment characteristics, and prognosis in primary operable colorectal cancer
por: Al‐Badran, Sara SF, et al.
Publicado: (2020)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Cooperation between chemotherapy and immune checkpoint blockade to enhance anti-tumour T cell immunity in oesophageal adenocarcinoma
por: Davern, Maria, et al.
Publicado: (2022)

Exosomes in tumour immunity
por: Clayton, A., et al.
Publicado: (2009)

Deciphering the tumour immune microenvironment cell by cell
por: Nabhan, M., et al.
Publicado: (2023)

Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma
por: Yan, Zi-Jun, et al.
Publicado: (2023)

Immunity to Transplanted Tumour: The Effect of Tumour Extracts on the Growth of Homologous Tumours in Rats
por: Baldwin, R. W.
Publicado: (1955)

Improved Anti-Tumour Adaptive Immunity Can Overcome the Melanoma Immunosuppressive Tumour Microenvironment
por: Dang, Nana, et al.
Publicado: (2019)

MUC1 modulates the tumor immune microenvironment through the engagement of Siglec-9
por: Beatson, Richard, et al.
Publicado: (2016)

Genomic and tumour microenvironmental biomarkers of immune checkpoint inhibitor response in advanced Taiwanese melanoma
por: Chang, John Wen‐Cheng, et al.
Publicado: (2023)

B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy
por: Tian, Xinyu, et al.
Publicado: (2023)

Targeting PPAR-gamma counteracts tumour adaptation to immune-checkpoint blockade in hepatocellular carcinoma
por: Xiong, Zhewen, et al.
Publicado: (2023)

Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours
por: Yen, Chih-Chieh, et al.
Publicado: (2023)

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity
por: Langdon, Sophie, et al.
Publicado: (2018)

Steroid-Functionalized Imidazolium Salts with an Extended Spectrum of Antifungal and Antibacterial Activity
por: Malinowska, Marta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iaghc2770u8m7vkartde3mpajr